Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | -321K | 0 | 0 | 0 |
| Operating Income | -30M | -65M | -11M | -3M |
| EBITDA | -30M | -63M | -1M | -12M |
| Net Income | -25M | -63M | -6M | -14M |
| EPS (Diluted) | — | — | — | — |
Healthcare
Live Price
Offline$30.61
+0.43% today
Window Change
+64.74%
Window
Sep 11, 2025 → Jun 15, 2026
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 190 bars · Sep 11, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
LB Pharmaceuticals Inc Common Stock (LBRX) is a Healthcare stock with a market cap of $900.00M and listed on NASDAQ. The stock last traded around $30.61 and up 64.7% across the available one-year price window (Sep 11, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +94.4%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +94.4%, free cash flow +34.5% with operating margin 0.0% and ROIC -9.9%. Stock Foundry combines LBRX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Edge
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
LBRX
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
LBRX Max Drawdown
-17.82%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for LBRX and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$14.3M
-128.7% YoY
Free Cash Flow
-$2.7M
+77.5% YoY
Revenue Growth
+0.0%
EPS Growth
+94.4%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | -321K | 0 | 0 | 0 |
| Operating Income | -30M | -65M | -11M | -3M |
| EBITDA | -30M | -63M | -1M | -12M |
| Net Income | -25M | -63M | -6M | -14M |
| EPS (Diluted) | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & Equivalents | 250M | 23M | 15M | 21M |
| Total Assets | 313M | 34M | 46M | 21M |
| Total Liabilities | 12M | 128M | 80M | 50M |
| Shareholder Equity | 301M | -95M | -34M | -29M |
| Total Debt | 4M | 4M | 0 | 24M |
| Net Debt | -247M | -19M | -15M | 3M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
3M
+77.4% YoY
Capital Expenditures
0
+100.0% YoY
Free Cash Flow
3M
+77.5% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-19.5%
Debt / Equity
0.01x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.